{
  "id": 17312559,
  "title": "trupanion COO John Gallagher sells $12,550 in company stock",
  "url": "https://urgent.news/2026/10/31/trupanion-coo-john-gallagher-sells-12-550-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-31T00:16:11.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/trupanion-coo-john-gallagher-sells-12550-in-company-stock-93CH-4988968"
  },
  "original_language": "en",
  "account": "Trupanion COO John Gallagher sold 431 shares of the company's common stock, totaling $12,550, on October 28, 2026. The shares were sold at $29.12 per share, reducing his direct ownership of Trupanion common stock to 32,880 shares. Trupanion's stock has shown a 26% return over the past six months, currently trading at $30.13. Despite this recent sale, the stock appears undervalued according to InvestingPro analysis, indicating potential upside for investors. Gallagher established a Rule 10b5-1 trading plan for this transaction on August 20, 2025. Trupanion reported stronger-than-expected Q2 2026 earnings, with earnings per share of $0.16, surpassing the forecasted $0.1133, and a 11% increase in revenue to $392.9 million. Analysts have mixed views on the company, with Piper Sandler downgrading Trupanion to Neutral from Overweight, citing macroeconomic headwinds, while acknowledging the company's strong market position and reputation among veterinarians.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}